Cowealth Medical China Co.,Ltd. (SHA:603122)
China · Delayed Price · Currency is CNY 10.52
-0.49 (-4.45%)
Oct 30, 2026, 4:00 PM EST
Cowealth Medical China Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 640 | 677.79 | 939.14 | 1,093 | 1,280 | 1,191 |
Revenue Growth | -17.64% | -27.83% | -14.05% | -14.62% | 7.44% | 9.37% |
Gross Profit Gross Profit Growth | 103.02 | 94.77 | 175.16 | 222.14 | 255.43 | 247.71 |
Operating Income Operating Income Growth | -24.09 | -41.3 | 35.07 | 64.48 | 98.87 | 102.03 |
Net Income Net Income Growth | -26.9 | -33.64 | 27.57 | 47.19 | 82.72 | 80.23 |
Earnings Per Share EPS Growth | -0.07 | -0.08 | 0.07 | 0.12 | 0.22 | 0.27 |
EPS Growth | - | - | -41.67% | -45.45% | -18.52% | 12.50% |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
In-Vitro Diagnostic Product Intensive Business In-Vitro Diagnostic Product Intensive Business Growth | 625.94 |
Medical Product Distribution Medical Product Distribution Growth | 50.54 |
Other Value-Added Services Other Value-Added Services Growth | 1.04 |
Total Total Growth | 677.51 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 140.34 | 149.44 | 260.84 | 197.89 | 336.86 | 146.6 |
Total Debt Total Debt Growth | 35.59 | 61.29 | 50.57 | 70.96 | 80 | 131.1 |
Net Cash (Debt) Net Cash Growth | 104.75 | 88.16 | 210.28 | 126.93 | 256.86 | 15.5 |
Net Cash Growth | -37.37% | -58.08% | 65.66% | -50.58% | 1556.84% | -88.19% |
Net Cash Per Share Net Cash Per Share Growth | 0.26 | 0.21 | 0.53 | 0.32 | 0.68 | 0.05 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -67.94 | 17.68 | 132.75 | 11.28 | -30.37 | 7.01 |
Capital Expenditures CapEx Growth | -11.66 | -14.21 | -31.82 | -67.96 | -25.94 | -22.12 |
Free Cash Flow Free Cash Flow Growth | -79.6 | 3.47 | 100.93 | -56.68 | -56.31 | -15.11 |
Free Cash Flow Growth | - | -96.56% | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 16.10% | 13.98% | 18.65% | 20.33% | 19.96% | 20.80% |
Operating Margin | -3.76% | -6.09% | 3.73% | 5.90% | 7.73% | 8.57% |
Pretax Margin | -4.98% | -5.92% | 4.20% | 6.01% | 8.90% | 9.19% |
Profit Margin | -4.20% | -4.96% | 2.94% | 4.32% | 6.46% | 6.74% |
FCF Margin | -12.44% | 0.51% | 10.75% | -5.19% | -4.40% | -1.27% |
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.130 | 0.060 | 0.150 | 0.180 |
Dividend Per Share Growth | 116.67% | -60.00% | -16.67% | - |
Dividend Yield | 1.85% | 0.74% | 1.34% | - |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 101.22 | 67.91 | 53.90 | - |
P/FCF Ratio | - | 2795.48 | 27.65 | - | - | - |
PS Ratio | 6.54 | 14.33 | 2.97 | 2.93 | 3.48 | - |